<DOC>
	<DOCNO>NCT01262989</DOCNO>
	<brief_summary>It open-label , randomize , laboratory-blind , crossover study 02 treatment , 02 sequence , 02 period , healthy male volunteer fast condition receive , period , test formulation reference formulation</brief_summary>
	<brief_title>SECOTEX® ( Tamsulosin Hydrochloride ) Bioequivalence Study Brazil - Fast Admin</brief_title>
	<detailed_description>TITLE : Randomized , two-period , cross-over , bioequivalence study tamsulosin hydrochloride 0,4 mg prolong release hard gelatin capsule ( Synthon BV , The Netherlands ) versus SECOTEX® ( tamsulosin hydrochloride ) 0,4 mg prolong release hard gelatin capsule ( Boehringer Ingelheim Brasil Química e Farmacêutica Ltda ) healthy male volunteer fast condition . It open-label , randomize , laboratory-blind , crossover study 02 treatment , 02 sequence , 02 period , healthy male volunteer fast condition receive , period , test formulation reference formulation . The treatment 's sequence attribute volunteer study period determine randomization list , generate PROC PLAN SAS version 9.1.3 system . The formulation administer single oral dose follow blood collection , least , 3 5 half-lives . The treatment 's period may obey minimum interval 7 half life ( period drug 's whole elimination organism ) .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>EXCLUSION CRITERIA : Known hypersensitivity study drug ( tamsulosin hydrochloride ) compound chemically related History presence hepatic gastrointestinal illness , condition interferes drug 's absorption , distribution , excretion metabolism History hepatic , renal , pulmonary , gastrointestinal , epileptic , hematologic psychiatric illness Hypotension hypertension etiologic need pharmacologic treatment Volunteer history myocardial infarction , angina and/or heart insufficiency Nonrecommended electrocardiographic finding , accord investigator criteria The result laboratory exams value consider normal accord protocol 's rule , unless consider clinically irrelevant investigator Volunteer smoker The volunteer ingest 5 cup coffee tea day History alcohol drug abuse History serious adverse reaction hypersensitivity drug Use regular drug within 02 week precede study 's initiation treatment within 03 previous month , precede study 's initiation , drug present toxic , consume inductive drug and/or enzymatic inhibitor ( CYP450 hepatic ) , within 04 week precede study 's initiation Hospitalization reason within 08 week begin study 's first period treatment post study assessment date Participation experimental study ingest experimental drug within 06 previous month Donation lose 450mL blood within 03 previous month Volunteer consume alcohol 48 hour prior admission study consume food beverage contain grapefruit 07 day previous study period INCLUSION CRITERIA : Male Age 18 50 year Body mass index ≥ 19 ≤28,5 Good health condition without significant illness , judgment legally qualify professional , accord rule define Protocol , accord follow evaluation : clinical history , pressure pulse measure , physical psychological exam , ECG , additional laboratory exam Capable understand study 's nature aim , include risk adverse effect intention cooperate researcher act compliance requirement whole assay ; confirm Informed Consent 's signature .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Tamsulosin</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Fast condition</keyword>
</DOC>